Retatrutide vs CagriSema: how the data compares

Two different bets on what comes after tirzepatide

Tirzepatide set the bar: 20.9% weight loss in SURMOUNT-1, the best FDA-approved result on the market. Both Eli Lilly and Novo Nordisk are now racing to clear it, and they picked different routes to do it. Retatrutide adds a third receptor, glucagon, to the GLP-1/GIP combination tirzepatide already uses. CagriSema skips GIP entirely and instead pairs semaglutide with an amylin analog, hitting satiety through the brainstem instead of the gut-brain axis GLP-1 already covers.

Both strategies work, on their own terms. Neither company has run its drug against the other's. What follows is the closest honest comparison available: matching each drug's own trial data side by side, with the caveats that come from doing that.

Retatrutide vs CagriSema: the weight loss numbers

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and ran to 80 weeks. The 12mg dose of retatrutide produced 28.3% mean weight loss, roughly 71.2 lbs on average. In the subgroup with BMI ≥35 who stayed on drug through week 104, that number reached 30.3%, putting retatrutide in the range of gastric bypass surgery without the surgery.

REDEFINE 1 enrolled 3,417 adults and ran to 68 weeks. CagriSema produced 22.7% mean weight loss, well ahead of semaglutide alone at 16.1% and cagrilintide alone at 11.8% in the same trial. About 60% of CagriSema participants lost at least a fifth of their body weight.

The 5.6-point gap between 28.3% and 22.7% is real, but it is not a fair fight. TRIUMPH-1 ran 12 weeks longer than REDEFINE 1, and weight loss on these drugs keeps climbing well past the one-year mark before it plateaus. A shorter trial will always understate a drug's eventual ceiling. The honest reading is that retatrutide is likely ahead, not that it is definitively ahead by exactly 5.6 points.

The one head-to-head that exists says something too

CagriSema has already been tested directly against tirzepatide. REDEFINE 4 put 809 adults on one drug or the other for 84 weeks. Tirzepatide won, 25.5% to 23%, and CagriSema failed the pre-specified non-inferiority threshold. That result matters here because it gives a rough anchor point: if CagriSema loses to tirzepatide, and retatrutide's own numbers run well ahead of tirzepatide's 20.9% in SURMOUNT-1, the gap between retatrutide and CagriSema is probably wider than the raw TRIUMPH-1/REDEFINE-1 numbers alone suggest.

That is inference, not data. Nobody has put retatrutide and CagriSema in the same trial, and until someone does, any ranking is built on cross-trial comparison, which is a weaker form of evidence than a direct test.

Why the mechanisms produce different results

Retatrutide's glucagon receptor sits mostly in the liver and pushes it to burn fatty acids directly, raising resting energy expenditure even at rest. That is a lever semaglutide, tirzepatide, and CagriSema do not have. It is also why retatrutide's liver fat data is so striking: an 86% reduction in a 2024 Phase 2 substudy, with 93% of participants returning to normal liver fat levels.

CagriSema's amylin component works through a different circuit, the brainstem's area postrema and nucleus tractus solitarius, rather than the hypothalamic pathway GLP-1 uses. Two genuinely separate satiety systems, stacked together, is a real idea, and REDEFINE 1 shows it adds meaningful weight loss on top of semaglutide alone. It just has not, so far, produced numbers that clear the bar GIP and glucagon combinations are setting.

Timeline: CagriSema is closer to a prescription

Regulatory status is where CagriSema has a clear lead. Novo Nordisk filed for FDA approval in December 2025, and a decision could land as early as late 2026. Eli Lilly has not yet filed retatrutide's new drug application; that submission is expected in Q4 2026, with a decision realistically in late 2027 at the earliest under standard review timelines.

That means CagriSema could realistically be prescribable close to a year before retatrutide, even if retatrutide ends up the stronger drug once both are on the market. Timing and efficacy are separate questions, and the drug that gets approved first will shape prescribing habits before the stronger drug even has a chance to compete.

Safety and tolerability

Retatrutide's GI adverse event rates run higher than tirzepatide's or semaglutide's at comparable doses. Nausea, vomiting, and diarrhea show up more often, though the trials have not surfaced organ-level toxicity or new cardiac signals beyond a mild heart rate increase already seen in Phase 2. CagriSema's adverse event profile in REDEFINE 1 tracked close to other GLP-1 drugs, dominated by GI symptoms that were mostly mild to moderate and transient. Neither drug has the years of real-world exposure that semaglutide and tirzepatide now have.

What this means if you need treatment now

Neither retatrutide nor CagriSema is something you can get prescribed today outside a clinical trial. The FDA has been active against gray-market vendors selling unapproved peptides, and quality control on that supply is not something to gamble health on.

Tirzepatide is approved, available, and already has a head-to-head win against CagriSema. If retatrutide's trajectory holds through Phase 3, it will likely outperform tirzepatide too, but that is at least 18 months away under an optimistic timeline. Starting tirzepatide now and switching later, once either newer drug clears the FDA, is a realistic path. See the current best GLP-1 programs for what is actually accessible today.